| [1] |
. Nat Rev Immunol，2020，20（1）：7-24.
|
| [2] |
Carreno B，Magrini V，Becker-Hapak M，et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells［J］. Science，2015，348（6236）：803-808.
|
| [3] |
Yamanaka R，Homma J，Yajima N，et al. 277. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma：results of a clinical phase I/II trial［J］. Clin Cancer Res，2005，11（11）：4160-4167.
|
| [4] |
Leonhartsberger N，Ramoner R，Falkensammer C，et al. Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma［J］. Cancer Immunol Immunother，2012，61（9）：1407-1413.
|
| [5] |
Draube A，Klein-Gonzalez N，Mattheus S，et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer：a systematic review and meta-analysis［J］. PLoS One，2011，6（4）：e18801.
|
| [6] |
Oshita C，Takikawa M，Kume A，et al. Dendritic cell-based vaccination in metastatic melanoma patients：phase II clinical trial［J］. Oncol Rep，2012，28（4）：1131-1138.
|
| [7] |
Evel-Kabler K，Song XT，Aldrich M，et al. SOCS1 restricts dendritic cells'' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling［J］. J Clin Invest，2006，116（1）：90-100.
|
| [8] |
Yoshimura A，Naka T，Kubo M. SOCS proteins，cytokine signalling and immune regulation［J］. Nat Rev Immunol，2007，7（6）：454-465.
|
| [9] |
Shen L，Evel-Kabler K，Strube R，et al. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity［J］. Nat Biotechnol，2004，22（12）：1546-1553.
|
| [10] |
Kanasty R，Dorkin JR，Vegas A，et al. Delivery materials for siRNA therapeutics［J］. Nat Mater，2013，12（11）：967-977.
|
| [11] |
Sioud M. Releasing the immune system brakes using siRNAs enhances cancer immunotherapy［J］. Cancers （Basel），2019，11（2）：176.
|
| [12] |
Troegeler A，Lastrucci C，Duval C，et al. An efficient siRNA‐mediated gene silencing in primary human monocytes，dendritic cells and macrophages［J］. Immunol Cell Biol，2014，92（8）：699-708.
|
| [13] |
Chen J，Ellert-Miklaszewska A，Garofalo S，et al. Synthesis and use of an amphiphilic dendrimer for siRNA delivery into primary immune cells［J］. Nat Protoc，2021，16（1）：327-351.
|
| [14] |
Crommelin DJA，Hoogevest P，Storm G. The role of liposomes in clinical nanomedicine development. What now？ Now what ［J］ ？J Control Release，2020，318：256-263.
|
| [15] |
Ahmed KS，Hussein SA，Ali AH，et al. Liposome：composition，characterisation，preparation，and recent innovation in clinical applications［J］. J Drug Target，2019，27（7）：742-761.
|
| [16] |
Gao A，Hu XL，Saeed M，et al. Overview of recent advances in liposomal nanoparticle-based cancer immunotherapy［J］. Acta Pharmacol Sin，2019，40（9）：1129-1137.
|
| [17] |
Kumar A，Baycin-Hizal D，Zhang Y，et al. Cellular traffic cops：the interplay between lipids and proteins regulates vesicular formation，trafficking，and signaling in mammalian cells［J］. Curr Opin Biotechnol，2015，36：215-221.
|
| [18] |
Lin ZM，Bao M，Yu ZX，et al. The development of tertiary amine cationic lipids achieves safe and efficient siRNA delivering［J］. Biomater Sci，2019，7（7）：2777-2792.
|
| [19] |
Wang R，Wang YM，Cai MJ，et al. Pharmacological effects of anti-melanoma DC vaccine sensitized by fusion proteins of G3G6 and HST1［J］. J China Pharm Univ（中国药科大学学报），2019，50（2）：238-245.
|
下载:
